MA32215B1 - Cristal de compose de benzimidazole - Google Patents

Cristal de compose de benzimidazole

Info

Publication number
MA32215B1
MA32215B1 MA33231A MA33231A MA32215B1 MA 32215 B1 MA32215 B1 MA 32215B1 MA 33231 A MA33231 A MA 33231A MA 33231 A MA33231 A MA 33231A MA 32215 B1 MA32215 B1 MA 32215B1
Authority
MA
Morocco
Prior art keywords
crystal
benzimidazole compound
benzimidazole
compound
crystals
Prior art date
Application number
MA33231A
Other languages
Arabic (ar)
English (en)
Inventor
Hideo Hashimoto
Tadashi Urai
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40577894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32215(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32215B1 publication Critical patent/MA32215B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un cristal de (r)-2-[[[3-méthyl-4-(2,2,2-trifluoroéthoxy)-2-pyridinyl]méthyl]sulfinyle]-1h-benzimidazole présentant un diagramme de diffraction des rayons x sur poudre ayant des pics caractéristiques à des distances réticulaires (d) de 10,06 ± 0,2, 8,70 ± 0,2, 6,57 ± 0,2, 5,59 ± 0,2 et 4,00 ± 0,2 angströms. La présente invention porte également sur un médicament antiulcéreux stable et supérieur en ce qui concerne la capacité d'absorption.
MA33231A 2008-03-10 2010-10-07 Cristal de compose de benzimidazole MA32215B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008059342 2008-03-10
PCT/JP2009/054970 WO2009113696A1 (fr) 2008-03-10 2009-03-09 Cristal de composé de benzimidazole

Publications (1)

Publication Number Publication Date
MA32215B1 true MA32215B1 (fr) 2011-04-01

Family

ID=40577894

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33231A MA32215B1 (fr) 2008-03-10 2010-10-07 Cristal de compose de benzimidazole

Country Status (30)

Country Link
US (1) US8222422B2 (fr)
EP (1) EP2262790B1 (fr)
JP (3) JP2011513202A (fr)
KR (1) KR20100123758A (fr)
CN (1) CN102026994B (fr)
AR (1) AR070972A1 (fr)
AU (1) AU2009224247B2 (fr)
BR (1) BRPI0909651A2 (fr)
CA (1) CA2671369C (fr)
CL (1) CL2009000547A1 (fr)
CO (1) CO6300956A2 (fr)
CR (1) CR11707A (fr)
DO (1) DOP2010000274A (fr)
EA (1) EA017064B1 (fr)
EC (1) ECSP10010531A (fr)
ES (1) ES2638463T3 (fr)
GE (1) GEP20125649B (fr)
IL (1) IL207867A0 (fr)
LT (1) LT2262790T (fr)
MA (1) MA32215B1 (fr)
MX (1) MX2010009641A (fr)
MY (1) MY150833A (fr)
NZ (1) NZ588379A (fr)
PE (1) PE20091680A1 (fr)
PT (1) PT2262790T (fr)
TW (1) TWI447110B (fr)
UA (1) UA103189C2 (fr)
UY (1) UY31695A (fr)
WO (1) WO2009113696A1 (fr)
ZA (1) ZA201006754B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004387A2 (fr) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Procédé de préparation de formes polymorphes du dexlansoprazole
CN102108077B (zh) * 2009-12-23 2013-09-25 江苏豪森医药集团有限公司 制备右兰索拉唑的方法
US20130197232A1 (en) * 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
CN104447695A (zh) * 2013-11-22 2015-03-25 广东东阳光药业有限公司 一种苯并咪唑化合物的水合物
EP3305291B1 (fr) 2015-06-08 2021-05-19 HK inno.N Corporation Utilisation de dérivé de benzimidazole pour l'acidité nocturne
BR122021026889A8 (pt) * 2016-11-29 2022-11-22 Censa Pharmaceuticals Inc Formas cristalinas de base livre de sepiapterina e de sais dos mesmos, seu método de preparação, composições que as compreendem, uso dos mesmos e método de preparação de uma formulação líquida
CN106866631A (zh) * 2017-04-06 2017-06-20 山东裕欣药业有限公司 一种右旋兰索拉唑晶型及制备方法
BR112020003865A8 (pt) 2017-09-01 2022-08-16 Censa Pharmaceuticals Inc Composições farmacêuticas compreendendo sepiapterina e seus usos
BR112020024019A2 (pt) * 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
EP3822249A4 (fr) * 2018-07-13 2022-04-13 Kyowa Hakko Bio Co., Ltd. Cristal de non-solvate d'acide eucomique et son procédé de production
CN113376273B (zh) * 2021-06-02 2023-03-17 国药集团精方（安徽）药业股份有限公司 一种清心莲子饮hplc特征图谱的检测方法及该特征图谱的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
EP0941102A1 (fr) 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions et methodes pour traiter des troubles gastro-intestinaux
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
AU2481899A (en) 1998-01-30 1999-08-16 Sepracor, Inc. S-lansoprazole compositions and methods
EP1056456A4 (fr) 1998-01-30 2006-10-25 Sepracor Inc Compositions et procedes d'utilisation du r-lansoprazole
AU3596199A (en) 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
KR101035534B1 (ko) * 2000-05-15 2011-05-23 다케다 야쿠힌 고교 가부시키가이샤 결정의 제조방법
JP4327424B2 (ja) * 2000-05-15 2009-09-09 武田薬品工業株式会社 結晶の製造法
JP3374314B2 (ja) * 2000-05-15 2003-02-04 武田薬品工業株式会社 結晶の製造法
JP4160293B2 (ja) * 2000-12-01 2008-10-01 武田薬品工業株式会社 結晶の製造法
KR100887912B1 (ko) 2000-12-01 2009-03-12 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정화 방법
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
US20100286400A1 (en) 2007-12-31 2010-11-11 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole

Also Published As

Publication number Publication date
JP2011513202A (ja) 2011-04-28
MY150833A (en) 2014-02-28
CO6300956A2 (es) 2011-07-21
GEP20125649B (en) 2012-09-25
ES2638463T3 (es) 2017-10-20
LT2262790T (lt) 2017-08-25
US8222422B2 (en) 2012-07-17
TW200938531A (en) 2009-09-16
PE20091680A1 (es) 2009-11-16
IL207867A0 (en) 2010-12-30
PT2262790T (pt) 2017-07-18
UY31695A (es) 2009-11-10
ZA201006754B (en) 2011-11-30
WO2009113696A1 (fr) 2009-09-17
AU2009224247B2 (en) 2013-12-12
EP2262790A1 (fr) 2010-12-22
EA201071053A1 (ru) 2011-04-29
US20110046183A1 (en) 2011-02-24
TWI447110B (zh) 2014-08-01
NZ588379A (en) 2012-07-27
AR070972A1 (es) 2010-05-19
UA103189C2 (ru) 2013-09-25
CN102026994B (zh) 2014-05-07
EA017064B1 (ru) 2012-09-28
EP2262790B1 (fr) 2017-06-07
CA2671369A1 (fr) 2009-09-10
JP2014015477A (ja) 2014-01-30
CA2671369C (fr) 2011-05-10
CN102026994A (zh) 2011-04-20
BRPI0909651A2 (pt) 2015-09-22
JP2015163623A (ja) 2015-09-10
CR11707A (es) 2010-11-04
DOP2010000274A (es) 2010-09-30
KR20100123758A (ko) 2010-11-24
AU2009224247A2 (en) 2010-10-28
ECSP10010531A (es) 2010-11-30
CL2009000547A1 (es) 2010-05-07
MX2010009641A (es) 2010-09-22
AU2009224247A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
MA32215B1 (fr) Cristal de compose de benzimidazole
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
CR20130045A (es) Compuestos terapéuticos
CR20120295A (es) Triazolopiridinas
MA32938B1 (fr) Composes organiques
CR20120348A (es) Nuevos compuestos tricíclicos
CR20140042A (es) Indazoles
EA200900945A1 (ru) Новый способ синтеза агомелатина
CO6592042A2 (es) Derivados de n3-sustituido -n1-sulfonil-5-fluorpirimidinona
HN2012000265A (es) Derivados de 5-fluoropirimidinona
CR20120565A (es) Indoles
CR20130233A (es) Derivados que quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinaza
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CR20120637A (es) Triazolopiridinas sustituidas
EA200900946A1 (ru) Новый способ синтеза агомелатина
EA201101675A1 (ru) Спироэпоксиды как промежуточные продукты синтеза
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
ECSP12011652A (es) Derivados de 5-fluoro-2-oxopirimidinona-1 (2h)-carboxamida substituida-n1
MA32610B1 (fr) Polymorphe b de n-(2-aminophenyl)-4-(n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl)-benzamide (ms-275)
ES2396795T8 (es) Compuesto de sulfonamida y cristal del mismo
EA200900943A1 (ru) Новый способ синтеза агомелатина
SV2009003345A (es) Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina
MA32474B1 (fr) Nouveaux derives de (piperazinyl ponte) -1-alcanone et leur utilisation comme inhibiteurs de p75
EA201200017A1 (ru) Новая кристаллическая форма пемироласта